Sitemap > Breaking Research > Psychiatric, Addictive & Sleep Disorders
Displaying 1 - 50 of 2259 results
- Effects of interleukin-1 and endotoxin in the forced swim and tail suspension tests in mice.
- Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials.
- Anxiolytic effects of benzalphthalides.
- Topiramate in treatment of depressive and anger symptoms in female depressive patients: a randomized, double-blind, placebo-controlled study.
- Screening of an endothelial cDNA library identifies the C-terminal region of Nedd5 as a novel autoantigen in systemic lupus erythematosus with psychiatric manifestations.
- The effects of curcumin on depressive-like behaviors in mice.
- Neurotensin-deficient mice have deficits in prepulse inhibition: restoration by clozapine but not haloperidol, olanzapine, or quetiapine.
- Genetic inactivation of melanin-concentrating hormone receptor subtype 1 (MCHR1) in mice exerts anxiolytic-like behavioral effects.
- Synthesis, structure-activity relationships, and anxiolytic activity of 7-aryl-6,7-dihydroimidazoimidazole corticotropin-releasing factor 1 receptor antagonists.
- Interaction of chiral MS-245 analogs at h5-HT6 receptors.
- QSAR study on thiazole and thiadiazole analogues as antagonists for the adenosine A1 and A3 receptors.
- Simultaneous use of thyrotropin-releasing hormone test and combined dexamethasone/corticotropine-releasing hormone test for severity evaluation and outcome prediction in patients with major depressive disorder.
- mGluR5, but not mGluR1, antagonist modifies MK-801-induced locomotor activity and deficit of prepulse inhibition.
- Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 4: 3-Alkyl-4-halo-6-nitroquipazines.
- A novel and selective monoamine oxidase B substrate.
- 5-HT1A receptor agonists modify epileptic seizures in three experimental models in rats.
- Regionally selective and dose-dependent effects of the ampakines Org 26576 and Org 24448 on local cerebral glucose utilisation in the mouse as assessed by 14C-2-deoxyglucose autoradiography.
- 4-Fluorosulfonylpiperidines: selective 5-HT2A ligands for the treatment of insomnia.
- Design, synthesis, and AMPA receptor antagonistic activity of a novel 6-nitro-3-oxoquinoxaline-2-carboxylic acid with a substituted phenyl group at the 7 position.
- Structure-activity studies of 3'-4'-dichloro-meperidine analogues at dopamine and serotonin transporters.
- Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.
- A randomized trial of citalopram versus placebo in outpatients with asthma and major depressive disorder: a proof of concept study.
- Synthesis of long-chain amide analogs of the cannabinoid CB1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716) with unique binding selectivities and pharmacological activities.
- Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial.
- A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression.
- Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction.
- Adamantyl cannabinoids: a novel class of cannabinergic ligands.
- Reversal of isolation-rearing-induced PPI deficits by an alpha7 nicotinic receptor agonist.
- Effects of apomorphine on rat behavior in the elevated plus-maze.
- Phenylpyrroles, a new chemolibrary virtual screening class of 5-HT7 receptor ligands.
- Discovery of a potent and selective 5-ht5A receptor antagonist by high-throughput chemistry.
- Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1.
- Indole- and indoline-based kainate analogues with antagonist activity at ionotropic glutamate receptors.
- Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGluR2): efficacy in an animal model for schizophrenia.
- 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles.
- 1-(4-Amino-phenyl)-pyrrolidin-3-yl-amine and 6-(3-amino-pyrrolidin-1-yl)-pyridin-3-yl-amine derivatives as melanin-concentrating hormone receptor-1 antagonists.
- Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers.
- Altered RNA editing of serotonin 2C receptor in a rat model of depression.
- Mice lacking Dlx1 show subtype-specific loss of interneurons, reduced inhibition and epilepsy.
- Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat.
- Gene expression profiling in the hippocampus of learned helpless and nonhelpless rats.
- The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab.
- Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function.
- Risperidone: an open-label, observational study of the efficacy, tolerability, and prescribing behavior in acutely exacerbated patients with schizophrenia.
- Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial.
- Effects of rivastigmine on sustained attention in schizophrenia: an FMRI study.
- Rapid antidepressant response after nocturnal TRH administration in patients with bipolar type I and bipolar type II major depression.
- The Texas implementation of medication algorithms update for treatment of bipolar I disorder.
- Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics.
- The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder.